Drawing for EXSCALATE

USPTO serial 79359829

EXSCALATE

Reviewed by CopyMark Law Group

Reg. 7383344Status 700Registered
Filing date
Status date
Registration date
May 14, 2024
Examiner
WATTS-FITZGERALD, CAITLIN C
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with EXSCALATE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
009Downloadable computer software for use in identifying new drugs, namely, software that is able to screen billions of compounds in a very short time and allows the identification of molecular targets, the identification and validation of candidate molecules, the proof-of-concept testing in selected pre-clinical models; downloadable computer software for use by doctors and other medical professionals in capturing, tracking, reporting, analyzing health data in the field of medical decision support systems; downloadable virtual reality software for medical teaching, specifically, for granting user access to courses of instruction in the medical field; downloadable virtual screening software, specifically, software that is able to screen billions of compounds in a very short time and allows the identification of molecular targets, the identification and validation of candidate molecules, and facilitates proof-of-concept testing in selected pre-clinical models; downloadable collaboration software platforms for use in database management in the field of medicine; downloadable computer software platforms for identifying new drugs in the nature of software that is able to screen billions of compounds in a very short time and allows the identification of molecular targets, the identification and validation of candidate molecules, the proof-of-concept testing in selected pre-clinical models; downloadable artificial intelligence software for identifying new drugs in the nature of software that is able to screen billions of compounds in a very short time and allows the identification of molecular targets, the identification and validation of candidate molecules, the proof-of-concept testing in selected pre-clinical models in the field of healthcareACTIVE
042Software as a service (SAAS) services featuring software platforms using artificial intelligence for use in identifying new drugs, namely, software that is able to screen billions of compounds in a very short time and allows the identification of molecular targets, the identification and validation of candidate molecules, the proof-of-concept testing in selected pre-clinical models; providing temporary use of online, non-downloadable artificial intelligence computer programs accessible via data networks for use in identifying new drugs, namely, software that is able to screen billions of compounds in a very short time and allows the identification of molecular targets, the identification and validation of candidate molecules, the proof-of-concept testing in selected pre-clinical models; research in the field of artificial intelligence; design and development of computer software for operating medical technology in the nature of software for use in identifying new drugs, namely, software that is able to screen billions of compounds in a very short time and allows the identification of molecular targets, the identification and validation of candidate molecules, the proof-of-concept testing in selected pre-clinical models; design and development of virtual screening software; design and development of virtual reality software for teaching medicineACTIVE

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 26, 2024TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 26, 2024ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 26, 2024REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 30, 2024FINOFINAL DECISION TRANSACTION PROCESSED BY IB
Nov 7, 2024FICSFINAL DISPOSITION NOTICE SENT TO IB
Nov 7, 2024FIMPFINAL DISPOSITION PROCESSED
Aug 14, 2024FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
May 14, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED
May 14, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 4, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 27, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 26, 2024GPNXNOTIFICATION PROCESSED BY IB
Feb 7, 2024OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 7, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 7, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 7, 2024OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jan 23, 2024PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY
Jan 11, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Jan 11, 2024XAECEXAMINER'S AMENDMENT ENTERED
Jan 11, 2024GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 11, 2024GNEAEXAMINERS AMENDMENT E-MAILED
Jan 11, 2024CNEAEXAMINERS AMENDMENT -WRITTEN
Jan 10, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Jan 10, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 10, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 17, 2023RFNTREFUSAL PROCESSED BY IB
Sep 25, 2023RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 25, 2023RFRRREFUSAL PROCESSED BY MPU
Sep 7, 2023RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 6, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 6, 2023DOCKASSIGNED TO EXAMINER
Jan 13, 2023MAFRAPPLICATION FILING RECEIPT MAILED
Jan 9, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 6, 2023REPRSN ASSIGNED FOR SECT 66A APPL FROM IB

Frequently asked questions

Related guidance